Literature DB >> 29324539

Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial.

Val Morrison, Llinos H Spencer, Nikki Totton, Kirstie Pye, Seow Tien Yeo, Caryl Butterworth, Liz Hall, Rhiannon Whitaker, Rhiannon Tudor Edwards, Laura J Timmis, Zoe Hoare, Richard D Neal, Clare Wilkinson, Simon Leeson.   

Abstract

OBJECTIVE: This study aimed to evaluate the feasibility of completing a parallel-group randomized controlled trial to compare usual follow-up care for women who have completed treatment of gynecological cancer against a nurse-led telephone intervention, known as Optimal Personalised Care After Treatment-Gynaecological.
METHODS: The unblinded trial aimed to recruit patients who had completed treatment of cervical, endometrial, epithelial ovarian, or vulval cancer within the previous 3 months at 3 North Wales hospitals. We randomized participants to either usual hospital-based follow-up or specialist nurse-led telephone education, empowerment, and structured needs assessment follow-up. The primary outcomes assessed the feasibility of running a larger trial including patient eligibility, recruitment and retention rates, and outcome measure completion. Secondary outcomes were generic and health-related quality of life and a patient self-report health service use (Client Service Receipt Inventory) data collected at 3 time points (baseline, 3 months, and 6 months).
RESULTS: Of the 58 women screened, 44 were eligible (76%) and 24 (55%) were recruited and randomized (12:12 to control and intervention, respectively). One participant was lost to follow-up. Recruited participants had a mean (SD) age of 60 (11.2) years and were approximately 5 months from their initial diagnosis (mean [SD], 159 [58] days). Seventeen (71%) of the participants had an endometrial cancer diagnosis. All outcome measure completion rates exceeded 96%. Although not a core feasibility objective, analyses of outcome measures indicated positive changes in quality of life and well-being within the Optimal Personalised Care After Treatment-Gynaecological group; exploratory cost consequence analysis indicated that the nurse-led intervention had a mean total service use cost of £27 per patient (bootstrapped 95% confidence interval, -£290 to £240) lower than did the standard care group.
CONCLUSION: Eligibility, recruitment, and retention rates as well as outcome measure completion showed that the trial is feasible.

Entities:  

Mesh:

Year:  2018        PMID: 29324539     DOI: 10.1097/IGC.0000000000001179

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

Review 1.  How Do We Follow Up Patients With Endometrial Cancer?

Authors:  Mette Moustgaard Jeppesen; Ole Mogensen; Dorte G Hansen; Stinne H Bergholdt; Pernille T Jensen
Journal:  Curr Oncol Rep       Date:  2019-05-15       Impact factor: 5.075

2.  'We do need to keep some human touch'-Patient and clinician experiences of ovarian cancer follow-up and the potential for an electronic patient-reported outcome pathway: A qualitative interview study.

Authors:  Fiona Kennedy; Leanne Shearsmith; Marie Holmes; Rosemary Peacock; Oana C Lindner; Molly Megson; Galina Velikova
Journal:  Eur J Cancer Care (Engl)       Date:  2022-02-10       Impact factor: 2.328

3.  An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer.

Authors:  Victory 'Segun Ezeofor; Llinos Haf Spencer; Simon N Rogers; Anastasios Kanatas; Derek Lowe; Cherith J Semple; Jeffrey R Hanna; Seow Tien Yeo; Rhiannon Tudor Edwards
Journal:  Pharmacoecon Open       Date:  2022-01-31

4.  Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.

Authors:  Fiona Kennedy; Leanne Shearsmith; Marie Holmes; Zoe Rogers; Rob Carter; Uschi Hofmann; Galina Velikova
Journal:  BMC Cancer       Date:  2022-07-02       Impact factor: 4.638

5.  Follow-up strategies following completion of primary cancer treatment in adult cancer survivors.

Authors:  Beverley L Høeg; Pernille E Bidstrup; Randi V Karlsen; Anne Sofie Friberg; Vanna Albieri; Susanne O Dalton; Lena Saltbæk; Klaus Kaae Andersen; Trine Allerslev Horsboel; Christoffer Johansen
Journal:  Cochrane Database Syst Rev       Date:  2019-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.